The authors are Blumberg Institute scientists and colleagues at the University of North Carolina. Abstract: Dihydroquinolizinones (DHQs) that inhibit cellular polyadenylating polymerases 5 and 7 (PAPD5 & 7), such as RG7834, have been shown to inhibit both
June 6, 2023 Taimoor Khan, PhD, has joined the Blumberg Institute as a Post Doctoral Research Fellow. He received his doctorate in biology at Shanghai Jiao Tong University in 2021. Prior to joining the Blumberg Institute Dr.
Nicholas A. Meanwell, PhD, former pharmaceutical industry scientist and executive and now distinguished professor at the Baruch S. Blumberg Institute, has been selected as the recipient of the 2024 Antonin Holý Award by the International Society for
A special issue of a major drug development journal published recently honors Nicholas A. Meanwell, PhD, a former pharmaceutical industry scientist and executive who now is a distinguished professor at the Baruch S. Blumberg Institute. The journal’s
There currently is no effective treatment for yellow fever, which kills thousands of people every year. Doylestown, Pa., Jan. 17, 2023 – The Baruch S. Blumberg Institute has been awarded a one-year contract by the National Institute
May 6, 2022 Thomas E. Shenk, PhD, has joined the Blumberg Institute’s faculty as Distinguished Professor of Experimental Therapeutics and Translational Medicines. Dr. Shenk is Emeritus James Elkins Professor of Life Sciences in molecular biology at Princeton